Last updated on February 2018

French Registry of First-line Treatment of Acute Promyelocytic Leukemia


Brief description of study

The registry aims to compare the two first-line available treatment approaches in non-high-risk APL patients aged 70 years - ATRA plus chemotherapy and ATRA plus ATO - in terms of practitioner's choice between the two options, clinical effectiveness and cost-effectiveness, long-term outcome, and short- and long-term toxic effects.

Detailed Study Description

  • Collection of epidemiological data on non-high-risk APL patients aged 70 years: age and sex distribution, medical history, prognostic factors (time to treatment start, severity of coagulopathy at presentation, Performance status).
    • Documentation of clinical and biologic effectiveness of the two first-line treatment approaches available for non-high-risk APL patients.
    • Documentation of Minimal Residual Disease (MRD).
    • Correlation of clinical outcomes with the chosen therapy.
    • Validation of published prognostic factors and identification of new prognostic factors

Clinical Study Identifier: NCT02938858

Contact Investigators or Research Sites near you

Start Over

CH Dr Schaffner

Lens, France
9.9miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.